Diphtheria
MONDO:0005504A Gram-positive bacterial infection caused by Corynebacterium diphtheriae. It usually involves the oral cavity, pharynx, and nasal cavity. Patients develop pseudomembranes in the affected areas and manifest signs and symptoms of an upper respiratory infection. The diphtheria toxin may cause myocarditis, polyneuritis, and other systemic effects.
27 clinical trials for this condition and its sub-types, 27 tagged with Diphtheria itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diphtheria
-
Anterior nasal diphtheria 0 trials
-
Cutaneous diphtheria 0 trials
-
Diphtheritic myocarditis 0 trials
-
Faucial diphtheria 0 trials
-
Laryngeal diphtheria 0 trials
-
Nasopharyngeal diphtheria 0 trials
-
Can one shot replace six? a new vaccine aims to protect infants from six diseases at once
Vaccine CompletedResearchers are testing a new vaccine called LBVD that combines protection against diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib into a single injection. The study will enroll healthy infants aged 6 to 8 weeks, who will receive three doses at 6, 10, and 14 week…
Phase 2/3 • Sponsor: LG Chem • Aim: Vaccine
Last updated Sep 05, 2026 00:00 UTC
-
Can a Five-Part vaccine bolster protection against three serious infections?
Vaccine CompletedThis trial evaluates a new five-component vaccine (Tdcp) designed to protect against diphtheria, tetanus, and pertussis (whooping cough). It includes about 1,820 participants aged 7 and older, who receive either the experimental vaccine or a control vaccine. The study measures ho…
Phase 2/3 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 28, 2026 00:00 UTC
-
Could a Lower-Dose polio vaccine help eradicate the disease?
Vaccine CompletedThis study tests a hexavalent vaccine that protects against six diseases, including polio, but uses a lower dose of the inactivated polio vaccine (IPV). The goal is to see if this reduced-dose version works as well as the standard full-dose vaccine in infants. Around 1,500 health…
Phase 3 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: Vaccine
Last updated Jul 03, 2026 00:00 UTC
-
Thousands monitored: is the whooping cough vaccine safe in real life?
Vaccine CompletedThis completed study tracked over 10,000 people in Thailand who received the Boostagen® vaccine, which protects against tetanus, diphtheria, and whooping cough. Healthcare workers reported any side effects to see how safe the vaccine is in everyday use. The study also looked at p…
Sponsor: BioNet-Asia Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 09:09 UTC
-
Hexaxim vaccine safety confirmed in 713 infants
Vaccine CompletedThis completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in every…
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 09:06 UTC
-
New combo vaccine for babies shows promise in large trial
Vaccine CompletedThis study tested a new vaccine called BK1310 in 370 healthy infants to see if it safely protects against several serious diseases: Hib, diphtheria, pertussis, tetanus, and polio. The vaccine was compared to existing vaccines. The goal was to check how well the infants' immune sy…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Vaccine
Last updated Jun 27, 2026 08:08 UTC
-
New combo vaccine shows promise in protecting infants from five serious diseases
Vaccine CompletedThis study tested a new vaccine called BK1310 in 267 healthy infants to see if it protects against tetanus, diphtheria, pertussis, polio, and bacterial meningitis as well as existing vaccines. Infants received three doses, and researchers measured their immune responses. The goal…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Vaccine
Last updated Jun 27, 2026 08:08 UTC
-
Booster shot study aims to keep teens safe from whooping cough
Vaccine CompletedThis study tested a booster dose of the DTaP vaccine (BK1301) in 446 adolescents aged 11-12 who had already received the standard childhood series. The goal was to confirm the vaccine boosts immunity against diphtheria, tetanus, and pertussis (whooping cough) safely. Results show…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Vaccine
Last updated Jun 27, 2026 08:08 UTC
-
New 6-in-1 shot for babies shows promise in thai trial
Vaccine CompletedThis study tested a new combination vaccine called Shan6™, which protects against six diseases (diphtheria, tetanus, whooping cough, hepatitis B, Hib, and polio) in healthy infants and toddlers in Thailand. The trial involved 460 participants and compared Shan6™ to a similar 5-in…
Phase 3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 07:51 UTC
-
New booster vaccine trial aims to shield japanese teens from three serious diseases
Disease control CompletedThis study tests a single booster dose of a combined vaccine against diphtheria, tetanus, and whooping cough (dTpa) in 85 healthy Japanese adolescents aged 11 to 13. Researchers will check if the shot triggers a strong immune response and monitor for side effects one month after …
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can extra tdap shots boost Life-Saving plasma?
Disease control CompletedThis study looks at whether giving the Tdap vaccine every 3 months for a year is safe for healthy plasma donors. Normally, this vaccine is given once every 10 years. The goal is to see if more frequent vaccination produces high levels of tetanus antibodies in the plasma, which co…
Phase 2 • Sponsor: ABO Holdings, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a new vaccine shield older kids and adults from three deadly infections?
Prevention CompletedThis early-stage trial is testing an experimental vaccine designed to protect people aged 6 and older against diphtheria, tetanus, and pertussis (whooping cough). The study will enroll 180 participants to check the vaccine's safety and how well it triggers an immune response. Som…
Phase 1 • Sponsor: CanSino Biologics Inc. • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Hospital push could shield seniors from preventable diseases
Prevention CompletedThis trial evaluates whether a hospital-based remedial vaccination strategy can improve Tdap-IPV (tetanus, diphtheria, pertussis, polio) vaccination rates in adults aged 65 and older in the Sarthe region of France. Participants are randomly assigned to receive either the remedial…
Sponsor: Centre Hospitalier le Mans • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Study: common chemicals could weaken vaccine power
Knowledge-focused CompletedThis study looked at whether exposure to PFAS chemicals (found in some water supplies) can weaken the body's immune response to the tetanus and diphtheria booster vaccine. Twenty adults from a community with known PFAS exposure received the vaccine and had blood and saliva sample…
Phase 4 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC